Trials / Unknown
UnknownNCT06165822
A Study to Evaluate Drug-Drug Interaction of TQB3909 Tablets
A Phase I Study to Evaluate Drug-Drug Interaction of TQB3909 Tablets
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This is a single-center, open, single-dose, self-controlled phase I clinical trial to evaluate the effects of Itraconazole Capsules/Rifampicin Capsules on pharmacokinetics of TQB3909 tablets in vivo, and the safety of TQB3909 tablets and combined with Itraconazole Capsules/Rifampicin Capsules after single oral dose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB3909 tablets | TQB3909 100mg/tablet. |
| DRUG | Itraconazole capsule | Itraconazole capsule is a strong inhibitor of CYP3A4. |
| DRUG | Rifampicin capsule | Rifampicin capsule is a strong inducer of CYP3A4. |
Timeline
- Start date
- 2023-12-01
- Primary completion
- 2024-01-01
- Completion
- 2024-03-01
- First posted
- 2023-12-12
- Last updated
- 2023-12-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06165822. Inclusion in this directory is not an endorsement.